Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma

Drug Delivery

Volumn 22, Issue 2, 2015, Pages 199-205

  Pandey, Vikas ^a   Gajbhiye, Kavita Rai ^a   Soni, Vandana ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Ligand; Lung cancer; Receptors; Solid lipid nanoparticles; Targeting

Indexed keywords

CYANAMIDE; LACTOFERRIN; NANOCARRIER; PACLITAXEL; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG; LUNG CARCINOMA; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CARCINOMA, BRONCHOGENIC; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; SOLUBILITY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, BRONCHOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; LACTOFERRIN; LUNG; LUNG NEOPLASMS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84921625067     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.877100     Document Type: Article

References (23)

1. Akunuru S, James Q, Zheng ZY. (2012). Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis 3:352-6.
2. Alkawash M, Head M, Alshami I, Soothill JS. (1999). The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains. J Antimicrob Chemother 44:385-7.
3. Bowes D, Clark AE, Corrin B. (1981). Ultrastructural localisation of lactoferrin and glycoprotein in human bronchial glands. Thorax 36:108-15.
4. Cavalli R, Caputo O, Gasco MR. (1993). Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 89:R9-12.
5. 2 nanoparticles under light and dark conditions at low exposure concentrations. Toxicol Res 1:116-30.
6. Elfinger M, Maucksch C, Rudolph C. (2007). Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28:3448-55.
7. Fujita K, Matsuda E, Sekine K, et al. (2004). Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25:1961-6.
8. Gibbons JA, Kanwar RK, Kanwar JR. (2011). Lactoferrin and cancer in different cancer models. Front Biosci (Schol Ed) 3:1080-8.
9. Gregory MM. (2012). Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen. Cleve Clinic J Med 79:32-7.
10. Hu FQ, Zhang Y, Du YZ, Yuan H. (2008). Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system. Int J Pharm 348:146-52.
11. Jain A, Agrawal A, Majumdar S, et al. (2010). Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Rel 148:359-67.
12. Kurmi BD, Gajbhiye V, Kayat J, Jain NK. (2011). Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. J Pharm Sci 100:2311-20.
13. Liao Y, Du X, Lonnerdal B. (2010). miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J Nutr 140:1552-6.
14. Liao Y, Du X, Lonnerdal B. (2011). Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46:459-77.
15. Mukherjee S, Ray S, Thakur RS. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71:349-58.
16. Provencio M, Isla D, Sánchez A, Cantos B. (2011). Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine. J Thorac Dis 3:197-204.
17. Rana S, Sharma S, Singh S. (2012). Iron binding and receptor: lactoferrin and tonb receptors. Int J Biomed Res 3:306-16.
18. Salim EI, Jazieh AR, Moore MA. (2011). Lung cancer incidence in the Arab league countries: risk, factors and control. Asian Pac J Cancer Prev 12:117-34.
19. Surapaneni MS, Das SK, Das NG. (2012). Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol 2012:1-15.
20. Wang LZ, Ho PC, Lee HS, et al. (2003). Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. J Pharm Biomed Anal 31:283-9.
21. Xu X, Veenstra TD. (2012). Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Genome Med 4:2-11.
22. Yong HY, Eunjoong K, Dai EP, et al. (2012). Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 80:268-73.
23. Zhao D, Zhao X, Zu Y, et al. (2011). Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomed 10:1-8.